These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17611409)

  • 1. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
    Xu XM; Zhou YQ; Wang MH
    J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
    Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
    Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
    Zhou YQ; He C; Chen YQ; Wang D; Wang MH
    Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
    Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
    Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
    Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
    Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
    Lu Y; Yao HP; Wang MH
    Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
    Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
    Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.
    Wei X; Hao L; Ni S; Liu Q; Xu J; Correll PH
    J Biol Chem; 2005 Dec; 280(48):40241-51. PubMed ID: 16166096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
    Zhang K; Zhou YQ; Yao HP; Wang MH
    Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.
    Wang MH; Kurtz AL; Chen Y
    Carcinogenesis; 2000 Aug; 21(8):1507-12. PubMed ID: 10910951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
    Chao KL; Tsai IW; Chen C; Herzberg O
    PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
    Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
    Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.